2016
Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2
Peguero J, Presti S, Issa O, Podesta C, Parise H, Layka A, Brenes J, Lamelas J, Lamas G. Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R2CHADS2. American Heart Journal 2016, 177: 153-159. PMID: 27297861, DOI: 10.1016/j.ahj.2016.04.019.Peer-Reviewed Original ResearchConceptsR2CHADS2 scoresOperative mortalityPermanent strokePostoperative eventsRenal failureCoronary artery bypass graft surgeryArtery bypass graft surgeryThoracic Surgeons scoreBypass graft surgeryCHA2DS2-VASc scorePostoperative renal failurePredictor of morbidityCongestive heart failureCardiac surgery outcomesEnd-point variablesCHA2DS2-VAScPrior strokeGraft surgeryPostoperative outcomesValve surgerySurgeons scoreHeart failureSurgery outcomesCardiovascular surgeryInclusion criteria
2011
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarction